

Unlocking pharma growth

Navigating
the intricacies
of emerging
markets

Unlocking pharma growth

Navigating the intricacies of emerging markets



Contents

1. Introduction



2. Rethinking the big pharma sales model: Thoughts from China

As the ranks of China's field forces continue to swell, pharma's traditional commercial model is showing signs of strain. It's time for multinationals to get smarter about how they sell.

Bing Chen, Franck Le Deu, and Jin Wang

10. Winning in the emerging middle class: Findings from Brazil

Global pharma companies are missing a chance to serve Brazil's increasingly prosperous and growing middle class. Although wealthier segments spend more on drugs per capita, the scale of the underserved middle-class market is almost twice as big.

Sanjeev Agarwal, João d'Almeida, Tracy Francis, and Paula Ramos

14. Using behavioral segmentation to boost salesforce effectiveness

Many companies segment their customers by behavioral characteristics to increase sales, but segmenting the field force is a new approach. Early experience in India suggests that it could improve salesforce effectiveness in emerging markets.

Kaustubh Chakraborty, Javed Kadir, and Sathya Prathipati

20. Counter strategies: Getting more value from the retail channel

Most pharma companies operating in emerging markets gear their sales and marketing efforts to physicians and hospitals. It's time they widened their horizons: building retail muscle could help them address a large and neglected opportunity.

Sanjeev Agarwal, Putney Cloos, Alka Goel, and Mary Rozenman

28. Public-private partnerships: An untapped strategic lever

Traditional approaches to PPPs have focused on their role in raising a company's profile or improving its corporate image. Now pharma companies are entering partnerships with governments and global organizations that deliver solid business benefits too.

Doan Hackley, Jorge Santos da Silva, and Lieven Van der Veken

36. How sustainable are branded generics?

Branded generics are delivering great growth and profitability in emerging markets, but how much longer can they continue to do so? A new approach helps companies assess the prospects market by market.

Sanjeev Agarwal, Andrew Cavey, and Ali Murad

42. Growth in Brazil's branded generics market: Perspectives from Maurizio Billi, president of Eurofarma

The leader of one of Brazil's most eminent pharma companies talks about building a platform for growth and how local players can capitalize on their market knowledge.

Nicola Calicchio and Tracy Francis

46. China's digital healing

The world's biggest and most dynamic social media market is talking about health care. But are companies really listening?



52. Breakthrough R&D for emerging markets: Critical for long-term success?

Pharma companies pursuing growth in emerging markets will increasingly need to adapt their portfolio to address local requirements. The right R&D strategy will involve reducing costs so that they can develop innovative drugs tailored to emerging market needs and still make a profit.

Sanjiv Talwar, Shail Thaker, and Matthew Wilson

60. Cutting through the complexity: Insights into the future of clinical trials in emerging markets

As investing in emerging market infrastructure becomes a pillar of pharma growth strategies, conducting clinical trials in these markets should be more attractive than ever. So why are such trials declining, and how should executives evaluate the opportunities in this increasingly complex environment?

Jackie Hua, Shail Thaker, and Matthew Wilson

66. Managing pharma supply networks in emerging markets

Before they rush to secure sources of supply in emerging markets, pharma companies should take care to ensure they have the right long-term strategy, the right partners, and the right organizational resources to manage their partnerships.

Vikas Bhadoria and Jaidev Rajpal

■ ■ ■

72. The outlook for China's medical products industry

Robust growth prospects are creating tailwinds for China's medical products industry. However, multinationals should prepare for turbulence ahead as market access becomes more complex, pricing pressures increase, and local competition intensifies.

Lifeng Chen, YINUO Li, Rajesh Parekh, and Jin Wang

80. Winning in Russia pharma: The next growth horizon

Over the next ten years Russian pharma will more than double in size. Companies seeking to capture a share of this growth must prepare to face the challenges of increasing pharma regulation and intensifying competition.

Jan Ascher, Sean O'Connell, Shail Thaker, and Tim Züwerink

92. Helping Indian pharma reach its full potential

What will it take for India to join the world's leading pharma markets? As a period of flux brings proliferating opportunities, companies should quickly adapt their sales and marketing models, refocus their commercial investments, and collaborate within and beyond the industry.

Vikas Bhadoria, Ankur Bhajanka, Kaustubh Chakraborty, and Palash Mitra

104. Tracking shifts and spotting opportunities in Mexican health care

Mexico's health care has improved thanks to recent public initiatives, but rising costs, capacity constraints, and growing disparities pose new challenges. To keep pace with these shifts, pharma companies need to raise their capabilities to global standard and preserve the flexibility to update their plans as often as every quarter.

Julio Dreszer, Pablo Ordorica, Lisa Ramon, Safa Sadeghpour, and Jorge Torres

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.